𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

✍ Scribed by Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl

Publisher
Springer US
Year
1990
Tongue
English
Weight
115 KB
Volume
8
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.

πŸ“œ SIMILAR VOLUMES

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p